Department of Cardio-Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
Eur J Cardiothorac Surg. 2013 Aug;44(2):e120-5; discussion e125. doi: 10.1093/ejcts/ezt219. Epub 2013 May 8.
Sublobar resection for early-stage lung cancer is still a controversial issue. We sought to compare sublobar resection (segmentectomy or wedge resection) with lobectomy in the treatment of patients with a second primary lung cancer.
From January 1995 to December 2010, 121 patients with second primary lung cancer, classified by the criteria proposed by Martini and Melamed, were treated at our Institution. We had 23 patients with a synchronous tumour and 98 with metachronous. As second treatment, we performed 61 lobectomies (17 of these were completion pneumonectomies), 38 atypical resections and 22 segmentectomies. Histology was adenocarcinoma in 49, squamous in 38, bronchoalveolar carcinomas in 14, adenosquamous in 8, large cells in 2, anaplastic in 5 and other histologies in 5.
Overall 5-year survival from second surgery was 42%; overall operative mortality was 2.5% (3 patients), while morbidity was 19% (22 patients). Morbidity was comparable between the lobectomy group, sublobar resection and completion pneumonectomies (12.8, 27.7 and 30.8%, respectively, P = 0.21). Regarding the type of surgery, the lobectomy group showed a better 5-year survival than sublobar resection (57.5 and 36%, respectively, P = 0.016). Compared with lobectomies, completion pneumonectomies showed a significantly less-favourable survival (57.5 and 20%, respectively, P = 0.001).
From our experience, lobectomy should still be considered as the treatment of choice in the management of second primary lung cancer, but sublobar resection remains a valid option in high-risk patients with limited pulmonary function. Completion pneumonectomy was a negative prognostic factor in long-term survival.
亚肺叶切除术治疗早期肺癌仍然存在争议。本研究旨在比较亚肺叶切除术(肺段切除术或楔形切除术)与肺叶切除术治疗第二原发性肺癌的效果。
1995 年 1 月至 2010 年 12 月,本机构共收治 121 例符合 Martini 和 Melamed 标准的第二原发性肺癌患者。23 例为同时性肿瘤,98 例为异时性肿瘤。作为第二治疗,我们进行了 61 例肺叶切除术(其中 17 例为全肺切除术)、38 例非典型切除术和 22 例肺段切除术。组织学类型为腺癌 49 例、鳞癌 38 例、细支气管肺泡癌 14 例、腺鳞癌 8 例、大细胞癌 2 例、未分化癌 5 例和其他组织学类型 5 例。
第二手术的总体 5 年生存率为 42%;总手术死亡率为 2.5%(3 例),发病率为 19%(22 例)。肺叶切除术组、亚肺叶切除术组和全肺切除术组的发病率分别为 12.8%、27.7%和 30.8%(P = 0.21),三组之间无显著差异。就手术类型而言,肺叶切除术组的 5 年生存率明显优于亚肺叶切除术组(分别为 57.5%和 36%,P = 0.016)。与肺叶切除术相比,全肺切除术的生存预后明显较差(分别为 57.5%和 20%,P = 0.001)。
根据我们的经验,肺叶切除术仍应作为第二原发性肺癌治疗的首选方法,但在肺功能有限的高危患者中,亚肺叶切除术仍是一种有效的选择。全肺切除术是影响长期生存的预后不良因素。